Journal
JOURNAL FOR IMMUNOTHERAPY OF CANCER
Volume 7, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s40425-019-0540-1
Keywords
-
Categories
Funding
- FONDECYT [1150731]
- Lung Cancer Research Foundation (LCRF)
- Yale SPORE in Lung Cancer [P50CA196530]
- Department of Defense-Lung Cancer Research Program Career Development Award [W81XWH-16-1-0160]
- Stand Up To Cancer - American Cancer Society Lung Cancer Dream Team Translational Research Grants [SU2C-AACR-DT17-15, SU2C-AACR-DT22-17]
- Yale Cancer Center Support Grant [P30CA016359]
- Navigate BioPharma
Ask authors/readers for more resources
BackgroundSmall cell lung cancer (SCLC) accounts for 10-15% of all lung malignancies and its prognosis is dismal. Although early studies have shown promising clinical activity of immune checkpoint blockers, the immune composition and expression of potentially actionable immunostimulatory targets in this malignancy are poorly understood.MethodsUsing multiplexed quantitative immunofluorescence (QIF), we measured the levels of 3 different B7 family ligands PD-L1, B7-H3, B7-H4 and major tumor infiltrating lymphocyte (TIL) subsets in 90 SCLC samples represented in tissue microarray format. Associations between the marker levels, clinicopathological variables and survival were studied.ResultsPD-L1 protein was detected in 7.3%, B7-H3 in 64.9% and B7-H4 in 2.6% of SCLC cases. The markers showed limited co-expression and were not associated with the level of TILs, age, gender and stage. Elevated B7-H4 was associated with shorter 5-year overall survival. The levels of CD3+, CD8+ and CD20+ TILs and the ratio of total/effector T-cells were significantly lower in SCLC than in non-small cell lung cancer. High levels of CD3+, but not CD8+ or CD20+ TILs were significantly associated with longer survival.ConclusionsTaken together, our study indicate variable expression and clinical role of B7-family ligands in SCLC with predominant expression of the candidate target B7-H3 and the presence of a limited cytotoxic anti-tumor immune response. These results support the evaluation of B7-H3 blockers and/or pro-inflammatory therapies in SCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available